lundi 21 janvier 2019

Onco Actu du 21 janvier 2019


2. ETIOLOGIE



FDA: Irbesartan lots recalled over likely carcinogen [UPI]











3.1.1 PRÉVENTION - TABAC - E-CIGS



FDA chief threatens to take e-cigarettes off the market [NBC]











4.12 BIOPSIES LIQUIDES



How new tests might help find treatments for cancers with no known origin [Cancer Research UK]










New combination blood test for pancreatic cancer may catch disease earlier [Van Andel Institute]











4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



Smear tests: women asked to discuss fears as test rate plummets [The Guardian]










5.10 TRAITEMENTS - ESSAIS



AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer [AbbVie]











AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study [Reuters]










5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Celgene strikes Obsidian deal to boost CAR-T options [Fierce Biotech]











Despite Buyout, Celgene Dealmaking Rolls On With Kyn, Obsidian Tie-Ups [Xconomy]











Celgene inks first deals since Bristol-Myers announced $74B buyout — bets $80M on immunometabolism [EndPoints]











5.12.6 IMMUNOTHÉRAPIES - AMM



Canada Health approves Novartis' CAR-T therapy Kymriah [Pharmafile]











5.2 PHARMA



On heels of Loxo buy, Lartruvo setback deals a blow to Lilly's oncology hopes [Fierce Pharma]











Failed Clinical Trial Puts Eli Lilly Cancer Drug in Limbo [Xconomy]










Lilly suspends Lartruvo promotion after Phase 3 failure [Biopharma Dive











Lilly’s approved cancer drug Lartruvo fails confirmatory study, setting the stage for withdrawal of regulatory endorsement [EndPoints]











Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO® [Lilly]











Lilly cancer drug fails key trial, will no longer be prescribed [Reuters]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod [Reuters]











5.5.5 ASCO (GASTRO-INTESTINAL)



Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients [Lilly]











Servier and Taiho Oncology Present Latest LONSURF® (trifluridine/tipiracil) Data at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI) [Servier]











6. LUTTE CONTRE LES CANCERS



Dr. John Mendelsohn, 82, Researcher Who Led Top Cancer Center, Dies [NY Times]